Trastuzumab deruxtecan (anti-ERBB2) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan (anti-ERBB2) is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan (anti-ERBB2) can be used for the research of HER2-positive breast cancer and gastric cancer.
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
图片
Trastuzumab deruxtecan (anti-ERBB2) (Ab183313) - Flow Cytometry Flow Cytometry analysis of MCF7 cells labelling ERBB2 (red) with Trastuzumab deruxtecan (anti-ERBB2) (Ab183313) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Trastuzumab deruxtecan (anti-ERBB2) (Ab183313) - ELISA Immobilized Recombinant Human ErbB2/HER2 protein (rp169607) at 1.0 μg/mL can bind Trastuzumab deruxtecan (anti-ERBB2) (Ab183313) with the EC₅₀ of 58.19 ng/mL.
Trastuzumab deruxtecan (anti-ERBB2) (Ab183313) - SEC The purity of Trastuzumab deruxtecan (anti-ERBB2) (Ab183313) is more than 95% verified by HPLC.